Story perspectives

Metabolon Partners with China Biobank to Tackle Health Disparities

9/10/2025

29 4

Summary

Story summary

Metabolon, Inc. collaborates with the China Kadoorie Biobank to investigate plasma metabolomics biomarkers related to common diseases, considering lifestyle, environmental, and genetic factors.
The study seeks to include underrepresented ethnic groups to better understand health disparities.
Metabolomics connects gene expression to physiology, supporting disease prevention and treatment.
The Lung Cancer Genetics Study by 23andMe plans to recruit over 10,000 lung cancer patients by 2027, focusing on diverse demographics.
Utilizing Lifebit's secure data platform, the study promotes transparency and patient involvement, with early results shared at the IASLC 2025 World Conference on Lung Cancer.

1 of 1

Story summary

Metabolon, Inc. collaborates with the China Kadoorie Biobank to investigate plasma metabolomics biomarkers related to common diseases, considering lifestyle, environmental, and genetic factors.
The study seeks to include underrepresented ethnic groups to better understand health disparities.
Metabolomics connects gene expression to physiology, supporting disease prevention and treatment.
The Lung Cancer Genetics Study by 23andMe plans to recruit over 10,000 lung cancer patients by 2027, focusing on diverse demographics.
Utilizing Lifebit's secure data platform, the study promotes transparency and patient involvement, with early results shared at the IASLC 2025 World Conference on Lung Cancer.